Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...
Sable Offshore rises 20.0%
Sable Offshore (SOC) is up 20.0%, or $4.90 to $29.37.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart ...
pharmaphorum2d
Opdivo's subcutaneous PD-1 inhibitor cleared in US
Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.
pharmaphorum6d
NICE says lung cancer breakthrough Opdivo too expensive
BMS's Opdivo has been rejected by NICE for use in patients with advanced lung cancer, the cost-effectiveness watchdog saying its price is too high to merit routine use.
inkbotdesign.com2d
Top 20 Fashion Logos: Best Designs in the Industry
Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...